Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

Inari Medical Reports Mixed Q4 Earnings, Guides FY22 Sales Above Consensus

Inari Medical Inc's (NASDAQ:NARIQ4 revenue was $83.2 million, up 14% sequentially and 71% Y/Y, beating the consensus of $78.16 million.

  • The sequential growth was driven by continued U.S. commercial expansion and new product introductions.
  • The gross margin was 90.1% compared to 92.4% a year ago, modestly lower primarily due to the move to its larger production facility in Q4 FY21.
  • Operating expenses reached $73.2 million, compared to $37.9 million in Q4 FY20, mainly driven by an increase in personnel-related costs on increased headcount to fund the expansion of the commercial, R&D, and clinical and support organizations.
  • Inari posted Q4 EPS of $0.02, down from $0.13 a year ago and below the consensus of $0.03.
  • The company treated 7,700 patients, up 15% sequentially. Over 90% of overall procedures and sequential procedural growth came from non-COVID patients.
  • Cash, cash equivalents, and short-term investments were $180.1 million.
  • Guidance: Inari Medical expects FY22 sales of $350 million - $360 million, reflecting a Y/Y growth of approximately 26% - 30%, compared to the consensus of $336.74 million.
  • Price Action: NARI shares closed lower by 1.63% at $76.00 on Wednesday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.